3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
16
Triple Negative Breast Neoplasms
13
Colorectal Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
7
Pancreatic Neoplasms
7
Carcinoma, Renal Cell
7
Stomach Neoplasms
6
Lymphoma
6
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Lung Neoplasms
4
Liver Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Nasopharyngeal Carcinoma
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Advanced Solid Tumor
3
Solid Tumors
2
Solid Tumor, Adult
2
Recurrence
2
Rectal Neoplasms
2
Interventions
uridine triacetate
1
spartalizumab
1
denileukin diftitox
1
Interleukin-2
1
Gemcitabine
1
Fluorouracil
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Drug-Related Side Effects and Adverse Reactions
×
spartalizumab
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled